GLP-1 drug shortages, driven by cosmetic and weight loss purposes, result in access disparities among individuals with ...

Some GLP-1 receptor agonists may hold promise as treatments for alcohol use disorder (AUD), a Swedish observational study ...

In addition to ensuring equitable access to the glucagon-like peptide-1 (GLP-1) receptor agonists, the medical community ...

A new study provides more evidence that GLP-1 RAs don’t raise the risk for pancreatic cancer and may in fact offer some protection.

A recent study conducted in Sweden found that GLP-1 agonists such as Ozempic and Wegovy may help reduce alcohol consumption and related harms in individuals diagnosed with alcohol use disorder.

Recent studies have shown that pharmacological treatment with GLP-1-RA and dual GLP-1/glucose-dependent insulinotropic ...

A new joint study by the University of Eastern Finland and Karolinska Institutet in Sweden found that the GLP-1 agonists semaglutide and liraglutide, which are used for treating diabetes and obesity, ...

Garner, MD, Medical Director at SimpleFixRx to review it all for accuracy. Dr, Garner said, "Glucagon-like peptide-1 (GLP-1) ...

The blockbuster drugs Ozempic and Wegovy may help people cut back on drinking, new research published Wednesday in JAMA ...

A new study says that type 2 diabetes medications GLP-1 agonists and SGLT2 inhibitors may help lower a stroke survivor’s risk of experiencing a subsequent stroke, heart attack, or death ...

The category is expected to scale to $8.7 billion by 2027. The market for GLP-1 agonist drugs also continues to grow and is expected to exceed $100 billion by 2030. NBJ's report aims to educate ...